6th Asia-Pacific Breast Cancer Summit

An interview about the importance of bone integrity through the breast cancer continuum

Patients with breast cancer have a high incidence of bone metastases and subsequent SREs, which are associated with a poorer prognosis. Patients with early-stage breast cancer treated with AIs are also at risk of fractures associated with CTIBL. Treatment with bone-targeting agents, such as denosumab, may prevent fractures in patients with early-stage breast cancer, and SREs in patients with breast cancer with bone metastases, while maintaining a favourable adverse event profile.

During the 6th Asia-Pacific Breast Cancer Summit, Professor Michael Gnant emphasized the need to maintain bone integrity in patients with breast cancer. Professor Gnant’s presentation highlighted the need to initiate early bone-targeted treatment in patients with breast cancer and bone metastases to prevent debilitating skeletal-related events (SREs). Patients with early-stage breast cancer receiving adjuvant aromatase inhibitor (AI) therapy also require bone-targeted treatment to prevent fractures related to cancer treatment-induced bone loss (CTIBL).

Interview with Dr. Michael Gnant